NCAM1 and thyroid gland disorder: In the present pilot study we seek to ascertain the efficacy of CD56 in discriminating between benign and malignant thyroid FNAC specimens and its role as an additional marker in the panel made up of HBME-1 and Galectin-3 as previously analyzed in some papers published by our group [12, 15, 16].